Search This Blog

Sunday, April 13, 2025

Top CDC Vaccine Safety Officer's Records Missing, HHS Says

 by Zachary Stieber via The Epoch Times,.

Records from a top official at the Centers for Disease Control and Prevention are missing, the CDC’s parent agency has informed a U.S. senator.

Department of Health and Human Services (HHS) officials told Sen. Ron Johnson (R-Wis.) in March that “they are having difficulty locating records,” Johnson said on April 9.

More recently, HHS officials said that Dr. Tom Shimabukuro’s records “remain lost and, potentially, removed from HHS’s email system altogether,” Johnson added.

Shimabukuro, the CDC, and HHS did not respond to requests for comment by publication time.

Shimabukuro is director of the CDC’s Immunization Safety Office, which researches the safety of vaccines, according to the CDC’s website. He frequently spoke at vaccine meetings, at times offering false information, The Epoch Times previously reported.

He was also involved in vaccine research, including monitoring vaccine safety in pregnant women.

Johnson, the chairman of the Senate’s Permanent Subcommittee on Investigations, disclosed the situation with Shimabukuro’s records in a letter to Attorney General Pam Bondi, FBI Director Kash Patel, and Juliet Hodgkins, the acting inspector general of HHS.

“Dr. Shimabukuro’s potential mishandling of his official records is highly concerning. His actions, if true, would have directly obstructed my multi-year oversight efforts of the COVID-19 vaccines and would be in clear violation of my November 19, 2024 demand to HHS, CDC, and the Food and Drug Administration to ‘preserve all records referring or relating to the development, safety, and efficacy of the COVID-19 vaccines,’” Johnson wrote.

“Furthermore, given Dr. Shimabukuro’s role at CDC, which includes monitoring adverse events relating to the COVID-19 vaccines, his communications are directly responsive to my January 28, 2025, subpoena to HHS for records relating to the development and safety of the COVID-19 vaccines. Any attempt to obstruct or interfere with my investigatory efforts would be grounds for contempt of Congress.”

The senator also said that if Shimabukuro mishandled records, he may have violated laws such as the Federal Records Act.

Johnson asked Bondi, Patel, and Hodgkins to investigate whether Shimabukuro and other officials within HHS deleted or destroyed agency records, including any attempts to avoid congressional oversight or Freedom of Information Act requests.

Spokespersons for the Department of Justice and HHS Office of Inspector General (OIG) confirmed in emails to The Epoch Times that the agencies received the letter, and declined to comment further. The FBI declined to comment.

Another HHS official, National Institutes of Health scientist Dr. David Morens, was previously revealed—through emails obtained via the Freedom of Information Act—to have talked about how he learned to make messages disappear after requests under the act were lodged.

“So I think we are all safe,” he wrote in one of the emails in 2021.

Johnson also requested an HHS inspector general investigation of Morens. The HHS hasn’t confirmed whether any probes were initiated, according to Johnson.

To date, the HHS OIG refuses to confirm that it has initiated any of these investigations. The HHS OIG’s lack of transparency with Congress is unacceptable,” Johnson wrote. “If the allegations regarding Dr. Shimabukuro’s mishandling of agency records are true, then it will certainly raise questions about the effectiveness of the HHS OIG’s oversight and cast doubt on whether the HHS OIG actually did what I asked it to do nineteen months ago.”

China imposes new export restrictions on rare earths

 China has imposed new export controls on seven additional rare earth elements (REEs) including yttrium, dysprosium and terbium, which are crucial to modern technology such as jet engines and electric vehicles, reported Reuters.

The move follows US President Donald Trump’s increase in tariffs on Chinese goods.

China’s inclusion of these elements on its dual-use export control list raises concerns over global supply chains.

The dual-use export control list does not guarantee outright export bans but allows for increased scrutiny of buyers, especially those linked to US military supply chains.

This has already led to a halt in Chinese exports of germanium and gallium to the US before a complete ban in December 2024.

The US Geological Survey estimates that global production of yttrium, one of the rare earths now under export restrictions, is no more than 20,000 tonnes (t) annually.

Despite their small quantities, these metals are ubiquitous in modern technology, highlighting the potential impact of China’s export controls.

China’s control over the rare earth market remains unchallenged, with the country accounting for around 60% of global mined production. It also dominates the processing stage, handling roughly 90% of global output.

Western countries are attempting to reduce dependence on Chinese rare earths by developing new mines and recycling projects. However, these initiatives are not yet close to competing with China’s production capabilities.

The new export controls are expected to cause immediate supply disruptions and could signal a decrease in Chinese rare earth supplies to Western military buyers.

While China has other critical metals it could leverage, the rare earth export ban seems to be a strategic option reserved for future use as trade tensions with the US continue to rise.

In February 2025, China imposed export restrictions on five key metals including tungsten and indium, which are critical to industries such as clean energy and defence.

Earlier this month, China also unveiled a set of countermeasures in response to US-imposed tariffs, intensifying the trade conflict between the two largest global economies.

https://www.mining-technology.com/news/china-rare-earth-export-control/

US Military Academies End Racial Preferences In Admissions

 by Bill Pan via The Epoch Times,

The U.S. Air Force Academy and the U.S. Military Academy at West Point said that race is no longer a factor in their admissions processes—a policy shift that could move ongoing litigations closer to settlement.

In separate letters sent Friday to federal courts in Colorado and New York, the academies requested a 60-day pause in the lawsuits brought against them by Students for Fair Admissions (SFFA), arguing that the admissions policies in question are no longer in effect.

SFFA, which secured a landmark victory in the Supreme Court in 2023 that struck down race-based admissions at both public and private universities, filed lawsuits against the military academies shortly after the ruling. At the time, the court explicitly exempted the academies from the same constitutional standards applied to civilian institutions, with Chief Justice John Roberts acknowledging that they may have “potentially distinct interests” in maintaining a racially diverse officer corps.

The policy changes that prompted the request for a pause, the academies said, stem from directives issued by President Donald Trump, whose administration is committed to dismantling diversity, equity, and inclusion (DEI) initiatives across all branches of the U.S. military as part a broader effort to refocus the military.

To implement the president’s vision for the military, Secretary of Defense Pete Hegseth has ordered his department to eliminate DEI initiatives and offices, including ceasing the practice of considering one’s race or sex when admitting cadets at military academies.

The U.S. Air Force Academy, based in Colorado Springs, stated in its letter that it has already ended race-based admissions practices following a series of White House and Pentagon directives. These include, most recently, a Feb. 6 memorandum issued by Acting Secretary of the Air Force Gwendolyn DeFilippi, who ordered the elimination of “quotas, objectives, and goals based on sex, race, or ethnicity for organizational composition, academic admission, career fields, or class composition.”

According to the Academy, the core constitutional question in the SFFA lawsuit is whether its prior policy violated the Fifth Amendment by allowing any consideration of race in admissions decisions. However, the service institution’s current admissions process “no longer permits any consideration of race, ethnicity, or sex.”

The Academy asked the court to stay the case for 60 days while it discusses with SFFA to determine whether the policy changes are sufficient grounds to resolve the case.

Similarly, West Point—located north of New York City—stated that it has taken all necessary steps to comply with the president’s orders and agency policy memoranda to ensure that race and ethnicity are no longer factors in admissions. The academy said it would use the 60-day period to continue talks with SFFA toward a possible settlement.

“At this time, the parties are continuing to discuss the details of West Point’s new policy and its effect on this litigation,” the school said in its own letter.

The development comes two weeks after the U.S. Naval Academy said it no longer considers race, ethnicity, or sex as a factor for admission, seeking to pause a lawsuit that was also brought by the SFFA. A federal judge ruled in December 2024 that the Annapolis-based academy could continue using racial preference in its admissions process.

Edward Blum, president of SFFA, didn’t immediately respond to a request for comment but has praised the Naval Academy’s decision.

“Students for Fair Admissions welcomes the announcement that the U.S. Naval Academy will end its unfair and illegal race-based admissions policies,” he said in a statement in March. “Racial discrimination is wrong and racial classifications have no place at our nation’s military academies.”

https://www.zerohedge.com/political/us-military-academies-end-racial-preferences-admissions

WI Teen Charged With Murdering Parents In 'Neo-Nazi' Satanic Plot To Kill Trump

 by Steve Watson via Modernity.news,

A 17-year-old kid from Wisconsin is suspected of murdering his own parents as part of a demented plot to assassinate President Trump and violently overthrow the government, according to charges outlined by local law enforcement.

The teenager, Nikita Casap, has been charged with two counts of first-degree intentional homicide of his own mother and stepfather, according to a Waukesha County Sheriff’s Department press release.

Casap has also been charged with hiding a corpse, misappropriating ID to obtain money, and theft of property over $10,000.

Investigators in the case say that Casap had put together a deranged fantasy whereby he would kill his own parents and use his inheritance to fund an assassinate attempt on Trump and simultaneously launch an anti-government insurgency.

He documented it in a manifesto titled “Accelerate the Collapse,” which was unveiled in a federal affidavit unsealed in the Eastern District of Wisconsin.

Referring to himself as “Awoken” and “accelerationist14,” the teenager detailed his plan to kill Trump, thereby igniting civil unrest all over the country.

He also wrote of kicking off a race war, in order to “save the white race from Jewish control,” manufacturing bombs, and assassinating “Jewish politicians and billionaires.”

When authorities recovered messages from Casap’s devices, they discovered that he had gotten as far as communicating with international accomplices, seeking out how to acquire explosives and drone weaponisation kits to deliver explosives and poisons, and was formulating an escape to Ukraine after completing “the job.”

Casap wrote that “There’ll never be a perfect revolutionary situation that springs up out of nowhere. We need to create a revolutionary situation ourselves. I do agree that only if terrorism is sustained over a period of time can it be effective.”

“In short, huge amounts of violence will be required,” he further declared, adding “Long past are the days when we can vote for a Hitler to save us. It is time we stop waiting. The best day to commit an attack is today, the next best is tomorrow.“

He further wrote, “It is time that we lead the way to the System collapse. Do absolutely anything you can that will lead to the collapse of America or any other country you live in. This is the only way that we can save the White race. White Revolution is the only solution.”

As this post further explains, Casap was also seemingly obsessed with the Satanic Order of Nine Angles:

The bodies of Casap’s parents were discovered on February 28 inside their home.

ABC News reports that in addition to the murder charges, investigators are pursuing federal charges consisting of conspiracy, attempted presidential assassination, and the use of weapons of mass destruction.

The unsealed search warrant affidavit in the case is below:

*  *  *

https://www.zerohedge.com/medical/wi-teen-charged-murdering-parents-neo-nazi-satanic-plot-kill-trump

QLGN stock touches 52-week low at $2.9 amid market challenges

 In a challenging market environment, Qualigen Therapeutics Inc. (QLGN) stock has reached a 52-week low, trading at $2.9, with data showing the company's market capitalization at just $2.31 million and an overall financial health score rated as WEAK. This price level reflects a significant downturn for the company, which has been navigating through a tough phase characterized by investor skepticism and broader market pressures. Over the past year, the stock has experienced a precipitous decline of 83.32%, with concerning metrics including a current ratio of 0.52 and negative earnings forecast of -$14.94 per share for FY2024. Ritter Pharmaceuticals, which merged with Qualigen in May 2020, has struggled to maintain stability. This sharp decrease underscores the volatility and the hurdles the company faces as it strives to stabilize and grow its market position amidst a competitive and ever-changing biopharmaceutical landscape. With short-term obligations exceeding liquid assets and negative EBITDA of -$6.89 million in the last twelve months, the company faces significant challenges ahead.

In other recent news, Qualigen Therapeutics has announced its intention to acquire Marizyme, marking a strategic move forward for the company. The acquisition, detailed in a non-binding Memorandum of Understanding, follows a co-marketing agreement established between the two companies in 2024. This potential acquisition involves Marizyme's flagship product, DuraGraft, an FDA-cleared technology used in Coronary Artery Bypass Graft surgeries. The market for these surgeries generates over $10 billion annually in the United States. Both Kevin Richardson II, CEO of Qualigen, and David Barthel, CEO of Marizyme, have expressed optimism about the acquisition, with expectations for rapid revenue growth starting in 2025. The deal's final structure and terms are subject to shareholder approval and the completion of due diligence. There is no guarantee that the transaction will be completed or that definitive agreements will be executed.

https://www.investing.com/news/company-news/qlgn-stock-touches-52week-low-at-29-amid-market-challenges-93CH-3980087

Organovo stock plunges to 52-week low

 Organovo Holdings Inc. (NASDAQ:ONVO), a pioneer in the field of bioprinting, has seen its stock tumble to $1.70, significantly below its 52-week high of $21.96. The stock's RSI indicates oversold conditions, while the company's Fair Value assessment suggests potential upside from current levels. This latest price level reflects a stark downturn for the company, with a 1-year decline of -82.36% and a concerning cash burn rate. Current ratio at 0.72 indicates short-term liquidity challenges. Investors have been wary as the company grapples with these financial hurdles, marking a tough phase for the innovative biotech firm. The steep fall to this year's low underscores the volatility and challenges Organovo faces in a competitive and rapidly evolving industry.

In other recent news, Organovo Holdings, Inc. disclosed its preliminary unaudited cash position for the fiscal year ending March 31, 2025. The company reported a cash and cash equivalents balance of approximately $11.3 million and estimated net cash usage of between $2.0 and $2.2 million for the fourth quarter. Organovo announced a 1-for-12 reverse stock split of its common stock to meet Nasdaq's minimum bid price requirement, effective after market close on March 20, 2025. This move was part of the company's efforts to maintain its Nasdaq listing, with the stock beginning to trade on a split-adjusted basis on March 21, 2025. Additionally, the company faces potential delisting from Nasdaq due to previously not meeting the minimum bid price requirement but plans to request a hearing to avoid delisting. Organovo may also receive a $5 million milestone payment within the next 12 months related to a Phase 2 clinical trial for an FXR agonist. The company could potentially earn up to $50 million in aggregate milestone payments from this trial. 

https://www.investing.com/news/company-news/organovo-stock-plunges-to-52week-low-touches-17-93CH-3981590

Integra LifeSciences stock hits 52-week low at $16.76

 Integra LifeSciences Holdings Corporation (IART), a leading global medical technology company with annual revenue of $1.61 billion, has seen its stock price touch a 52-week low, reaching $16.76.  This latest price level reflects a significant downturn from the company's performance over the past year, with the stock experiencing a 1-year change of -48.14%. While investors are closely monitoring Integra's strategic moves and market conditions, Management has been actively buying back shares, and analysts expect net income growth in the coming year. 

In other recent news, Integra LifeSciences reported its financial results for the fourth quarter of 2024, revealing an earnings per share (EPS) of $0.97, which surpassed the forecast of $0.8543. Despite a slight revenue miss, with $442.65 million against a forecast of $445.14 million, the company demonstrated resilience with an 11.5% increase in reported revenue compared to the previous year. The firm's strategic expansion into international markets and product innovation were highlighted as key growth drivers. However, challenges such as declining gross and EBITDA margins were noted, indicating areas needing improvement. In another development, Argus upgraded Integra LifeSciences' stock rating to "Buy" with a price target of $28, citing the resolution of supply issues and the appointment of Mojdeh Poul as CEO as positive factors. Meanwhile, Citizens JMP maintained a "Market Outperform" rating with a $35 price target, acknowledging operational challenges but expressing confidence in the company's long-term prospects. These recent developments reflect a mixed outlook for Integra LifeSciences, balancing operational hurdles with strategic initiatives aimed at growth.

https://www.investing.com/news/company-news/integra-lifesciences-stock-hits-52week-low-at-1676-93CH-3981717